Anesthesia and analgesia
-
Anesthesia and analgesia · Nov 1999
Randomized Controlled Trial Clinical TrialThe effective dose of dexamethasone for antiemesis after major gynecological surgery.
This double-blind, randomized, placebo-controlled study evaluated the minimum effective dose of dexamethasone for postoperative antiemesis. One-hundred fifty women scheduled for major gynecological surgery were randomly assigned to receive dexamethasone 10 mg (D10), 5 mg (D5), 2.5 mg (D2.5), 1.25 mg (D1.25), or placebo (P) before the induction of general anesthesia. A standardized general anesthesia technique was used. Postoperative pain was treated with bolus IV doses of morphine via a patient-controlled analgesia device. Patients were assessed for incidence of vomiting at 4, 8, 12, and 24 h after surgery. A total of 6, 6, 8, 15, and 19 patients in Groups D10, D5, D2.5, D1.25, and Group P experienced vomiting at least once within the first postoperative 24 h, respectively. Dexamethasone 10 mg, 5 mg, and 2.5 mg was more effective than dexamethasone 1.25 mg or placebo for antiemesis (P < 0.05). The difference in antiemetic effect among the 10 mg, 5 mg, and 2.5 mg groups was similar. The results suggest that 2.5 mg is the minimum effective dose of dexamethasone for postoperative antiemesis in patients undergoing general anesthesia for major gynecological surgery. ⋯ Although dexamethasone is effective for antiemesis, major side effects may accompany its perioperative use. To achieve the best antiemesis with the fewest side effects, dexamethasone 10 mg, 5 mg, 2.5 mg, and 1.25 mg were compared with placebo in surgical patients. We found 2.5 mg to be the minimum effective dose without discernible side effects.
-
Anesthesia and analgesia · Nov 1999
Randomized Controlled Trial Comparative Study Clinical TrialTwo doses of intrathecal sufentanil (2.5 and 5 microg) combined with bupivacaine and epinephrine for labor analgesia.
In this study, we evaluated the effect of two doses of intrathecal sufentanil combined with bupivacaine and epinephrine on the incidence of pruritus and on the duration and quality of analgesia. One hundred five parturients were enrolled in this randomized, double-blinded, placebo-controlled study. They received either intrathecal 1.25 mg bupivacaine and 25 microg epinephrine (control group); 1.25 mg bupivacaine, 25 microg epinephrine, and 2.5 microg sufentanil (2.5-microg group); or 1.25 mg bupivacaine, 25 microg epinephrine, and 5 microg (5-microg group). Pain relief was assessed 10 min after injection, and pruritus was recorded at 30 min by a blinded observer. The study ended when the parturients requested further analgesia. There were no demographic differences among groups. Ninety of 103 parturients achieved complete pain relief with the initial dose, 11 patients in the control group (P < 0.004, control versus both sufentanil groups), and 2 patients in the 2.5-microg group needed a supplemental epidural bupivacaine. Pruritus was absent in the control group (P < 0.0001, control versus both sufentanil groups), whereas it was present in 36% of the 2.5-microg group and in 66% of the 5-microg group (P = 0.015, 2.5-microg versus 5-microg group). The mean duration of analgesia was similar in patients receiving sufentanil (2.5-microg group: 133 +/- 55 min; 5-microg group: 142 +/- 52 min) but was significantly higher than the control group (56 +/- 32 min). Reducing the sufentanil dose from 5 microg to 2.5 microg when combined with bupivacaine and epinephrine, decreases the incidence of pruritus without impeding the quality or duration of analgesia. ⋯ We evaluated two different doses of intrathecal sufentanil combined with bupivacaine and epinephrine for labor analgesia. Sufentanil 2.5 microg offered an advantage over sufentanil 5 microg because, while providing the same quality and duration of analgesia, it was associated with a reduced incidence of pruritus.
-
Anesthesia and analgesia · Nov 1999
Randomized Controlled Trial Clinical TrialAttempting to maintain normoglycemia during cardiopulmonary bypass with insulin may initiate postoperative hypoglycemia.
We attempted to develop an insulin administration protocol that maintains normoglycemia in patients undergoing cardiac surgery and to study the effects of intraoperative blood glucose management on serum levels of creatine phosphokinase isoenzyme BB (CK-BB) and S-100 protein. Twenty nondiabetic patients were randomly allocated to receive either "tight control" of blood glucose with a standardized IV insulin infusion intraoperatively (Group TC) or "no control" of blood glucose intraoperatively (Group NC). Perioperative serum levels of glucose, CK-BB, and S-100 protein were determined in all patients. Group TC patients received 90.0 +/- 49.2 units of insulin, whereas Group NC patients received none. Despite insulin, both Group TC (P = 0.00026) and Group NC (P = 0.00003) experienced similar significant increases in blood glucose levels during hypothermic cardiopulmonary bypass. However, mean blood glucose level upon intensive care unit arrival was significantly decreased in Group TC, compared with Group NC (84.7 +/- 41.0 mg/dL, range 32-137 mg/dL vs 201.4 +/- 67.5 mg/dL, range 82-277 mg/dL, respectively; P = 0.0002). Forty percent of Group TC patients required treatment for postoperative hypoglycemia (blood glucose level <60 mg/dL). Substantial interindividual variability existed in regard to insulin resistance. The investigation was terminated after we realized that normoglycemia was unattainable with the study protocol and that postoperative hypoglycemia was unpredictable. All patients in both groups experienced similar significant increases in postoperative serum levels of CK-BB and S-100 protein. These results indicate that "tight control" of intraoperative blood glucose in nondiabetic patients undergoing cardiac surgery was unattainable with the study protocol and may initiate postoperative hypoglycemia. ⋯ The appropriate intraoperative management of hyperglycemia and whether it adversely affects neurologic outcome in patients after cardiac surgery remains controversial. This investigation reveals that attempting to maintain normoglycemia in this setting with insulin may initiate postoperative hypoglycemia.
-
Anesthesia and analgesia · Nov 1999
Randomized Controlled Trial Clinical TrialThe use of a remifentanil infusion for hemodynamic control during intracranial surgery.
Remifentanil is an extremely rapid and short-acting opioid analgesic which is effective in controlling acute stress responses during surgery. During neurosurgical anesthesia, laryngoscopy and intubation, application of the head holder, scalp incision, and the craniectomy can produce significant increases in mean arterial pressure (MAP). In this dose-response study, we evaluated the efficacy of a remifentanil infusion in maintaining hemodynamic stability during intracranial surgery under desflurane anesthesia. Forty-five patients were assigned randomly to one of the three remifentanil infusion groups. All patients received a standardized anesthetic induction consisting of midazolam, 2 mg IV, lidocaine 0.75 mg/kg IV, propofol 1.0 mg/kg IV, and remifentanil 0.5 microg/kg IV. Immediately after induction of anesthesia, a remifentanil infusion was started at 0.0625 microg x kg(-1) x min(-1) (Group 1), 0.125 microg x kg(-1) x min(-1) (Group 2), or 0.250 microg x kg (-1) x min(-1)(Group 3) according to a double-blinded study protocol. Maintenance of anesthesia consisted of desflurane 3% (end-tidal) in air/oxygen. If the MAP exceeded 80 mm Hg, a supplemental bolus of remifentanil, 0.5 microg/kg IV was administered, and when the MAP decreased below 65 mm Hg, the remifentanil infusion was discontinued temporarily. "Rescue" cardiovascular medications consisted of nitroprusside (100 microg IV) or phenylephrine (100 microg IV). Heart rate, systolic, diastolic, and MAP values, were recorded every minute for 20 min after each specific stimulus. The overall quality of the intraoperative hemodynamic control was evaluated by the attending anesthesiologist on a scale from 1 = poor to 5 = excellent. The overall quality of the hemodynamic control was superior in Group 2 compared with Group 1 (P < 0.05). Although the total dose of remifentanil administered during the study period did not differ among the three groups, Group 1 required significantly more supplemental boluses of remifentanil (66%-80%) than Groups 2 (13%-33%) and 3 (70% 13%), and the remifentanil infusion was discontinued more often in Group 3 (80%-93%) than in Groups 1 (0%-13%) and 2 (21%-40%). In conclusion, the recommended remifentanil infusion rate for controlling acute autonomic responses during neurosurgical anesthesia is 0.125 microg x kg(-1) x min(-1) when administered during a desflurane-based anesthetic. ⋯ Compared with remifentanil 0.0625 microg x kg(-1) x min(-1) and 0.250 microg x kg(-1) x min(-1), a remifentanil infusion rate of 0.125 microg x kg(-1) x min(-1) provided more stable hemodynamic conditions during intracranial surgery under desflurane anesthesia.
-
Anesthesia and analgesia · Nov 1999
Randomized Controlled Trial Comparative Study Clinical TrialVisual estimation of onset time at the orbicularis oculi after five muscle relaxants: application to clinical monitoring of tracheal intubation.
The onset time of neuromuscular blockade at the adductor pollicis (AP) is different among neuromuscular blocking drugs, but these discrepancies had never been studied at the orbicularis oculi (OO). The purpose of this study was to verify if the differences in onset time observed at the AP still existed at the OO and to score the intubating conditions using monitoring at the OO after five muscle relaxants. The study included 172 adults aged 18-75 yr. Anesthesia was induced with fentanyl and propofol. Atracurium (0.5 mg/kg), mivacurium (0.20 mg/kg), rocuronium (0.6 mg/kg), succinylcholine (1.0 mg/kg), or vecuronium (0.08 mg/kg) was injected by random allocation. Time to complete disappearance of the response at the OO was assessed visually after train-of-four stimulation of the facial nerve. Laryngoscopy was then performed, and intubating conditions were determined on a scale of 1-4. Results were based on 150 patients. Onset time at the OO was (mean +/- SD): succinylcholine (57 +/- 17 s) < mivacurium (99 +/-19 s) = rocuronium (99 +/- 47 s) < atracurium (129 +/-33 s) = vecuronium (135 +/- 38 s) (P < 0.05). Overall intubating conditions were excellent (84%), good (14%), poor (1.3%), impossible (0.7%), and were similar among the five groups. We conclude that differences in onset time of muscle relaxants observed at the AP were also found at the OO. Visual estimation of the response at the OO correctly predicted good-to-excellent intubating conditions in more than 90% of cases for all the currently available muscle relaxants. ⋯ Onset time of neuromuscular blockade, as estimated visually at the orbicularis oculi, depends on the muscle relaxants given. Regardless of the relaxant used, intubating conditions at loss of orbicularis oculi are acceptable.